Pipeline

We’re working with our partners to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes first-in-class therapies aimed at providing new solutions and cancer support where no options currently exist, and helping to lift the burden of cancer for patients.

Clinical Research

We are committed to clinical research with a program of 21 trials from Phase I to III with more than 6,500 patients in 747 centers globally between 2014 and 2016.

pipeline sito 1pipeline sito 3

 

2014-2016 Research Summary

6,617

Patients Tested

Patients Tested

747

Clinical Centres

Clinical Centres

One Epidemiological Study

Pipeline

Cancer Supportive Care
Cancer Therapeutics
Metabolism
Compound Indication Phase
Netupitant-Palonosetron
Fixed Combination IV - Worldwide
Chemotherapy-Induced Nausea and Vomiting Regulatory
Netupitant-Palonosetron
Fixed Combination Oral - China - Korea
Chemotherapy-Induced Nausea and Vomiting Regulatory
PALONOSETRON IV and ORAL - CHINA Chemotherapy-Induced Nausea and Vomiting Regulatory
Anamorelin - Europe Cancer Anorexia-Cachexia in NSCLC* patients Regulatory
Palonosetron - China PONV** Phase 3
Anamorelin - China Cancer Anorexia-Cachexia in NSCLC* patients Phase 3
Anamorelin - US Cancer Anorexia-Cachexia in NSCLC* patients Phase 3
ANAMORELIN JAPAN*** Cancer Anorexia-Cachexia in patients with GI tract cancers Phase 3
Netupitant-Palonosetron
Fixed Dose Combination Oral
Chronic Nausea and Vomiting in Cancer Patients Phase 2
Netupitant-Palonosetron
Oral Suspension
Chemotherapy-Induced Nausea ORAL SUSPENSION and Vomiting in Pediatric Patients Phase 2
Netupitant IV - Japan**** Chemotherapy-Induced Nausea and Vomiting Phase 2
Anamorelin Cancer-Related Fatigue Phase 2
Elsiglutide Chemotherapy-Induced Diarrhea (various settings) Phase 2
HM01 - Ghrelin Receptor Agonist 1 Chemotherapy-Induced Neuropathic Pain Phase 1
HM03 - Ghrelin Receptor Agonist 2 Cancer Anorexia-Cachexia Research
*NSCLC (Non Small Cell Lung Cancer)
**Post-Operative Nausea and Vomiting
*** Managed by Helsinn’s partner in Japan: Ono Pharmaceutical
**** Managed by Helsinn’s partner in Japan: Taiho Pharmaceutical
Compound Indication Phase
Pracinostat Acute Myeloid Leukaemia (AML) Phase 3
Pracinostat Myelodysplastic Syndrome (MDS) Phase 2
HM05 - Ret Inhibitor NSCLC* with RET mutations Preclinical
*NSCLC (Non Small Cell Lung Cancer)
Compound Indication Phase
HM04 - Ghrelin Receptor Antagonist Prader-Willi Syndrome Preclinical
Ghrelin Receptor Inverse Agonists Obesity Research